StockMacro
Menu

Edwards Lifesciences

$101.85 +16% in 6 monthsMarket cap $58.6B

EW on XNYS, Health Care, Edwards Lifesciences Corp, job postings

Measures activity, not value. Not investment advice.

Net income fell 25% over 12 months while quarterly revenue rose 10% to $1.7B.

  • GoodShares up 15% in one month and 21% over the past year
  • BadApplications to hire foreign specialists fell 35%, to 41 from 63

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.

Industry
Orthopedic, prosthetic & surgical appliances & supplies (Health Care)
Employees
16,000
Website
edwards.com
Listed
NYSE, US
Last results
4 Nov 2026
Next results
expected around 9 Feb 2027 (an estimate: a year ago it reported on 10 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $1.7B, net income $307.5M.
Quarter to 31 Dec 2021: revenue $1.3B, net income $335.3MQuarter to 31 Dec 2021: revenue $1.3B, net income $335.3MQuarter to 31 Mar 2022: revenue $1.3B, net income $373.6MQuarter to 31 Mar 2022: revenue $1.3B, net income $373.6MQuarter to 30 Jun 2022: revenue $1.4B, net income $406.4MQuarter to 30 Jun 2022: revenue $1.4B, net income $406.4MQuarter to 30 Sep 2022: revenue $1.3B, net income $343.5MQuarter to 30 Sep 2022: revenue $1.3B, net income $343.5MQuarter to 31 Dec 2022: revenue $1.3B, net income $398.4MQuarter to 31 Dec 2022: revenue $1.3B, net income $398.4MQuarter to 31 Mar 2023: revenue $1.5B, net income $340.5MQuarter to 31 Mar 2023: revenue $1.5B, net income $340.5MQuarter to 30 Jun 2023: revenue $1.5B, net income $307.1MQuarter to 30 Jun 2023: revenue $1.5B, net income $307.1MQuarter to 30 Sep 2023: revenue $1.5B, net income $384.9MQuarter to 30 Sep 2023: revenue $1.5B, net income $384.9MQuarter to 31 Dec 2023: revenue $1.3B, net income $369.9MQuarter to 31 Dec 2023: revenue $1.3B, net income $369.9MQuarter to 31 Mar 2024: revenue $1.6B, net income $351.9MQuarter to 31 Mar 2024: revenue $1.6B, net income $351.9MQuarter to 30 Jun 2024: revenue $1.4B, net income $366.3MQuarter to 30 Jun 2024: revenue $1.4B, net income $366.3MQuarter to 30 Sep 2024: revenue $1.4B, net income $3.1BQuarter to 30 Sep 2024: revenue $1.4B, net income $3.1BQuarter to 31 Dec 2024: revenue $1.4B, net income $385.6MQuarter to 31 Dec 2024: revenue $1.4B, net income $385.6MQuarter to 31 Mar 2025: revenue $1.4B, net income $358.0MQuarter to 31 Mar 2025: revenue $1.4B, net income $358.0MQuarter to 30 Jun 2025: revenue $1.5B, net income $333.2MQuarter to 30 Jun 2025: revenue $1.5B, net income $333.2MQuarter to 30 Sep 2025: revenue $1.6B, net income $291.1MQuarter to 30 Sep 2025: revenue $1.6B, net income $291.1MQuarter to 31 Dec 2025: revenue –, net income $91.2MQuarter to 31 Mar 2026: revenue $1.6B, net income $380.7MQuarter to 31 Mar 2026: revenue $1.6B, net income $380.7MQuarter to 30 Jun 2026: revenue $1.7B, net income $241.9MQuarter to 30 Jun 2026: revenue $1.7B, net income $241.9MQuarter to 30 Sep 2026: revenue $1.7B, net income $307.5MQuarter to 30 Sep 2026: revenue $1.7B, net income $307.5M
31 Dec 2021RevenueNet incometallest bar $3.1B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$1.7B$307.5M
30 Jun 2026$1.7B$241.9M
31 Mar 2026$1.6B$380.7M
31 Dec 2025–$91.2M
30 Sep 2025$1.6B$291.1M
30 Jun 2025$1.5B$333.2M
31 Mar 2025$1.4B$358.0M
31 Dec 2024$1.4B$385.6M
30 Sep 2024$1.4B$3.1B
30 Jun 2024$1.4B$366.3M
31 Mar 2024$1.6B$351.9M
31 Dec 2023$1.3B$369.9M
30 Sep 2023$1.5B$384.9M
30 Jun 2023$1.5B$307.1M
31 Mar 2023$1.5B$340.5M
31 Dec 2022$1.3B$398.4M
30 Sep 2022$1.3B$343.5M
30 Jun 2022$1.4B$406.4M
31 Mar 2022$1.3B$373.6M
31 Dec 2021$1.3B$335.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $6.7B $5.9B
Revenue growthRevenue of the last 12 months compared with the 12 months before. +13% +8.1%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. $1.0B $1.4B
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). $1.77 $2.32
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 78.0% 78.2% 61.3%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. 21.6% 24.2% 5.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. 15.3% 23.2% -2.7%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. 9.7% -20.0%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $1.4B $804.2M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $4.6B $3.8B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $598.8M $598.2M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$4.0B (net cash) -$3.2B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.06 0.22
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $18.89
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. 57.3 27.5
P/SPrice to sales: market cap divided by revenue of the last 12 months. 8.8 2.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 8.2 3.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.4 3.4

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Edwards LifesciencesEW (this company) $58.6B57.38.8+13%15.3%
SterisSTE $24.8B30.04.0+8.1%13.4%
Intuitive SurgicalISRG $138.3B46.811.0+21%23.5%
Zimmer BiometZBH $19.1B24.92.2+7.0%9.0%
Align TechnologyALGN $10.9B22.22.6+4.6%11.7%
Mine SafetyMSA $6.5B21.63.3+8.1%15.0%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$10.9M

bought $0, sold $10.9M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+1.9%

1,332 13F filers vs 1,307

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

88%

506.9M shares held by 13F filers (30 Sep 2026) of 575.0M outstanding (31 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

1.6%

9.4M shares sold short (30 Oct 2026) of 575.0M outstanding (31 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

2.8

9.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+0.5%

9.3M shares sold short in the report before, 9.4M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

45%

45% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 44%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

362

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-35%

41 vs 63 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+10%

$1.7B vs $1.6B (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+11%

$63.6M vs $57.5M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$28.8M

the 12 months before: $28.1M

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$1.3M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

25

25 articles in the last 7 days; its usual week has 5 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

5.0×

25 articles in the last 7 days; its usual week has 5.

Price $101.85 on 20 Nov 2026, +21% over 12 months (12-month range $75.87 to $107.15)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $34.1M in the last 12 months (the 12 months before: -$13.6M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 41 published in the last 12 months, -35% on the 12 months before.
Revenue per quarter. Revenue $1.7B in the latest quarter, +10% on a year earlier.
Capital spending per quarter. Capital spending $63.6M in the latest quarter, +11% on a year earlier.
Institutional holders (13F filers). 1,332 13F filers reported holding it in the latest 13F quarter, +12% on a year earlier.
Federal obligations. Federal obligations: $29.6M published in the last 12 months, +8.6% on the 12 months before.
Lobbying spend. Lobbying spend: $1.3M published in the last 12 months, -8.0% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
16 Nov 2026Lobbying filingnew lobbying registration (MARSHALL & POPP, LLC)
28 Aug 20268-K and other filingsDirector or officer change
28 Aug 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Jun 2026Lobbying filingnew lobbying registration (AKIN GUMP STRAUSS HAUER & FELD)
8 May 20268-K and other filingsDirector or officer change
4 May 20268-K and other filingsDirector or officer change
4 May 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
17 Mar 2026Sharp changeShort interest spike: short interest spike, 12.4M vs usual 7.9M (2026-02-27); 1.5x the same period a year earlier
26 Feb 2026Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 97.4M vs usual 56.8M (2025-12-31); 2.0x the same period a year earlier
30 Oct 20258-K and other filingsDirector or officer change
30 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
24 Jul 20258-K and other filingsDirector or officer change
8 May 20258-K and other filingsDirector or officer change
8 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
10 Jul 20248-K and other filingsDirector or officer change
17 Jun 20248-K and other filingsDirector or officer change
26 Mar 20248-K and other filingsDirector or officer change
26 Mar 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 May 20238-K and other filingsDirector or officer change
15 May 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
28 Mar 2023Sharp changeShort interest spike: short interest spike, 16.9M vs usual 6.6M (2023-03-15); 3.8x the same period a year earlier
14 Feb 2023Sharp changeShort interest spike: short interest spike, 13.7M vs usual 6.3M (2023-01-31); 2.4x the same period a year earlier
31 Jan 2023Sharp changeShort interest spike: short interest spike, 13.9M vs usual 6.0M (2023-01-13); 2.6x the same period a year earlier
17 Jan 2023Sharp changeShort interest spike: short interest spike, 15.3M vs usual 5.8M (2022-12-30); 2.8x the same period a year earlier
3 Jan 2023Sharp changeShort interest spike: short interest spike, 14.0M vs usual 5.8M (2022-12-15); 2.5x the same period a year earlier
13 Dec 2022Sharp changeShort interest spike: short interest spike, 11.0M vs usual 5.7M (2022-11-30); 1.9x the same period a year earlier
8 Dec 20228-K and other filingsDirector or officer change
8 Dec 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
29 Nov 2022Sharp changeShort interest spike: short interest spike, 10.6M vs usual 5.7M (2022-11-15); 1.9x the same period a year earlier
21 Jul 20228-K and other filingsA major agreement ended
Insider net buying (open market)
Month from 1 Nov 2021: $157K published
Month from 1 Dec 2021: -$8.2M published
Month from 1 Jan 2022: -$6.0M published
Month from 1 Feb 2022: -$12.8M published
Month from 1 Mar 2022: -$9.3M published
Month from 1 Apr 2022: -$13.2M published
Month from 1 May 2022: -$9.0M published
Month from 1 Jun 2022: -$4.7M published
Month from 1 Jul 2022: -$3.6M published
Month from 1 Aug 2022: -$4.1M published
Month from 1 Sep 2022: -$2.9M published
Month from 1 Oct 2022: -$3.2M published
Month from 1 Nov 2022: -$2.7M published
Month from 1 Dec 2022: -$2.9M published
Month from 1 Jan 2023: -$2.4M published
Month from 1 Feb 2023: -$3.1M published
Month from 1 Mar 2023: -$2.9M published
Month from 1 Apr 2023: -$3.9M published
Month from 1 May 2023: -$17.5M published
Month from 1 Jun 2023: -$4.0M published
Month from 1 Jul 2023: -$4.9M published
Month from 1 Aug 2023: -$4.6M published
Month from 1 Sep 2023: -$5.3M published
Month from 1 Oct 2023: -$3.9M published
Month from 1 Nov 2023: -$3.4M published
Month from 1 Dec 2023: -$5.3M published
Month from 1 Jan 2024: -$2.9M published
Month from 1 Feb 2024: -$10.8M published
Month from 1 Mar 2024: -$6.0M published
Month from 1 Apr 2024: -$6.0M published
Month from 1 May 2024: -$6.0M published
Month from 1 Jun 2024: -$978K published
Month from 1 Jul 2024: -$514K published
Month from 1 Aug 2024: -$418K published
Month from 1 Sep 2024: -$334K published
Month from 1 Oct 2024: -$348K published
Month from 1 Nov 2024: -$2.0M published
Month from 1 Dec 2024: -$1.5M published
Month from 1 Jan 2025: -$378K published
Month from 1 Feb 2025: -$2.3M published
Month from 1 Mar 2025: -$2.7M published
Month from 1 Apr 2025: -$684K published
Month from 1 May 2025: -$1.4M published
Month from 1 Jun 2025: -$2.2M published
Month from 1 Jul 2025: -$327K published
Month from 1 Aug 2025: -$904K published
Month from 1 Nov 2025: -$1.2M published
Month from 1 Dec 2025: -$5.2M published
Month from 1 Jan 2026: -$1.1M published
Month from 1 Feb 2026: -$3.7M published
Month from 1 Mar 2026: -$2.2M published
Month from 1 Apr 2026: -$2.9M published
Month from 1 May 2026: -$6.7M published
Month from 1 Jun 2026: -$46K published
Month from 1 Jul 2026: -$1.2M published
Month from 1 Aug 2026: -$3.3M published
Month from 1 Sep 2026: -$104K published
Month from 1 Oct 2026: -$53K published
Month from 1 Nov 2026: -$7.5M published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 9 published
Quarter from 1 Apr 2022: 13 published
Quarter from 1 Jul 2022: 22 published
Quarter from 1 Oct 2022: 20 published
Quarter from 1 Jan 2023: 11 published
Quarter from 1 Apr 2023: 12 published
Quarter from 1 Jul 2023: 15 published
Quarter from 1 Oct 2023: 10 published
Quarter from 1 Jan 2024: 9 published
Quarter from 1 Apr 2024: 7 published
Quarter from 1 Jul 2024: 22 published
Quarter from 1 Oct 2024: 25 published
Quarter from 1 Jan 2025: 7 published
Quarter from 1 Apr 2025: 17 published
Quarter from 1 Jul 2025: 30 published
Quarter from 1 Oct 2025: 9 published
Quarter from 1 Jan 2026: 12 published
Quarter from 1 Apr 2026: 6 published
Quarter from 1 Jul 2026: 18 published
Quarter from 1 Oct 2026: 5 published
Revenue per quarter
Quarter ended 31 Dec 2021: $1.3B, +12% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $1.3B, +10% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $1.4B, -0.2% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $1.3B, +0.7% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $1.3B, +1.4% on a year earlier; public on 14 Feb 2023
Quarter ended 31 Mar 2023: $1.5B, +8.8% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $1.5B, +11% on a year earlier; public on 29 Jul 2023
Quarter ended 30 Sep 2023: $1.5B, +12% on a year earlier; public on 28 Oct 2023
Quarter ended 31 Dec 2023: $1.3B, -6.1% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2024: $1.6B, +9.5% on a year earlier; public on 30 Apr 2024
Quarter ended 30 Jun 2024: $1.4B, -9.4% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $1.4B, -8.5% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $1.4B, +9.4% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $1.4B, -12% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $1.5B, +11% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $1.6B, +15% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Mar 2026: $1.6B, +17% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $1.7B, +14% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $1.7B, +10% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $89.8M, -21% on a year earlier; public on 15 Feb 2022
Quarter ended 31 Mar 2022: $72.7M, -31% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $43.1M, -38% on a year earlier; public on 30 Jul 2022
Quarter ended 30 Sep 2022: $59.9M, -1.3% on a year earlier; public on 29 Oct 2022
Quarter ended 31 Dec 2022: $68.9M, -23% on a year earlier; public on 14 Feb 2023
Quarter ended 31 Mar 2023: $61.5M, -15% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $47.9M, +11% on a year earlier; public on 29 Jul 2023
Quarter ended 30 Sep 2023: $55.3M, -7.7% on a year earlier; public on 28 Oct 2023
Quarter ended 31 Dec 2023: $88.3M, +28% on a year earlier; public on 13 Feb 2024
Quarter ended 31 Mar 2024: $65.3M, +6.2% on a year earlier; public on 30 Apr 2024
Quarter ended 30 Jun 2024: $85.4M, +78% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $51.9M, -6.1% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $49.8M, -44% on a year earlier; public on 1 Mar 2025
Quarter ended 31 Mar 2025: $56.0M, -14% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $49.3M, -42% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $57.5M, +11% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $97.4M, +96% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $64.9M, +16% on a year earlier; public on 7 May 2026
Quarter ended 30 Jun 2026: $66.9M, +36% on a year earlier; public on 5 Aug 2026
Quarter ended 30 Sep 2026: $63.6M, +11% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 1,169; public on 14 Feb 2022
31 Mar 2022 report: 1,215; public on 16 May 2022
30 Jun 2022 report: 1,189; public on 15 Aug 2022
30 Sep 2022 report: 1,138; public on 14 Nov 2022
31 Dec 2022 report: 1,108; public on 14 Feb 2023
31 Mar 2023 report: 1,155; public on 15 May 2023
30 Jun 2023 report: 1,171; public on 14 Aug 2023
30 Sep 2023 report: 1,116; public on 14 Nov 2023
31 Dec 2023 report: 1,143; public on 14 Feb 2024
31 Mar 2024 report: 1,205; public on 15 May 2024
30 Jun 2024 report: 1,225; public on 14 Aug 2024
30 Sep 2024 report: 1,124; public on 14 Nov 2024
31 Dec 2024 report: 1,164; public on 14 Feb 2025
31 Mar 2025 report: 1,144; public on 15 May 2025
30 Jun 2025 report: 1,195; public on 14 Aug 2025
30 Sep 2025 report: 1,188; public on 14 Nov 2025
31 Dec 2025 report: 1,276; public on 17 Feb 2026
31 Mar 2026 report: 1,258; public on 15 May 2026
30 Jun 2026 report: 1,307; public on 14 Aug 2026
30 Sep 2026 report: 1,332; public on 16 Nov 2026
Federal obligations
Month from 1 Nov 2021: $254K published
Month from 1 Dec 2021: $1.4M published
Month from 1 Jan 2022: $1.3M published
Month from 1 Feb 2022: $1.5M published
Month from 1 Mar 2022: $1.9M published
Month from 1 Apr 2022: $1.8M published
Month from 1 May 2022: $2.5M published
Month from 1 Jun 2022: $1.1M published
Month from 1 Jul 2022: $1.4M published
Month from 1 Aug 2022: $1.9M published
Month from 1 Sep 2022: $2.1M published
Month from 1 Oct 2022: $2.1M published
Month from 1 Nov 2022: $1.8M published
Month from 1 Dec 2022: $1.8M published
Month from 1 Jan 2023: $1.7M published
Month from 1 Feb 2023: $1.7M published
Month from 1 Mar 2023: $1.5M published
Month from 1 Apr 2023: $1.5M published
Month from 1 May 2023: $2.2M published
Month from 1 Jun 2023: $1.1M published
Month from 1 Jul 2023: $1.9M published
Month from 1 Aug 2023: $2.4M published
Month from 1 Sep 2023: $2.2M published
Month from 1 Oct 2023: $3.2M published
Month from 1 Nov 2023: $1.8M published
Month from 1 Dec 2023: $2.2M published
Month from 1 Jan 2024: $1.7M published
Month from 1 Feb 2024: $3.1M published
Month from 1 Mar 2024: $2.5M published
Month from 1 Apr 2024: $1.8M published
Month from 1 May 2024: $2.1M published
Month from 1 Jun 2024: $2.4M published
Month from 1 Jul 2024: $2.9M published
Month from 1 Aug 2024: $2.5M published
Month from 1 Sep 2024: $2.4M published
Month from 1 Oct 2024: $2.6M published
Month from 1 Nov 2024: $1.9M published
Month from 1 Dec 2024: $2.3M published
Month from 1 Jan 2025: $1.8M published
Month from 1 Feb 2025: $1.7M published
Month from 1 Mar 2025: $2.5M published
Month from 1 Apr 2025: $1.8M published
Month from 1 May 2025: $2.7M published
Month from 1 Jun 2025: $2.3M published
Month from 1 Jul 2025: $3.5M published
Month from 1 Aug 2025: $2.3M published
Month from 1 Sep 2025: $2.2M published
Month from 1 Oct 2025: $2.0M published
Month from 1 Nov 2025: $2.2M published
Month from 1 Dec 2025: $3.0M published
Month from 1 Jan 2026: $1.5M published
Month from 1 Feb 2026: $2.0M published
Month from 1 Mar 2026: $2.0M published
Month from 1 Apr 2026: $3.3M published
Month from 1 May 2026: $2.7M published
Month from 1 Jun 2026: $3.0M published
Month from 1 Jul 2026: $2.3M published
Month from 1 Aug 2026: $2.2M published
Month from 1 Sep 2026: $3.4M published
Month from 1 Oct 2026: $2.3M published
Month from 1 Nov 2026: $1.8M published
Lobbying spend
Quarter from 1 Jan 2022: $340K published
Quarter from 1 Apr 2022: $260K published
Quarter from 1 Jul 2022: $330K published
Quarter from 1 Oct 2022: $310K published
Quarter from 1 Jan 2023: $350K published
Quarter from 1 Apr 2023: $430K published
Quarter from 1 Jul 2023: $370K published
Quarter from 1 Oct 2023: $330K published
Quarter from 1 Jan 2024: $380K published
Quarter from 1 Apr 2024: $430K published
Quarter from 1 Jul 2024: $380K published
Quarter from 1 Oct 2024: $350K published
Quarter from 1 Jan 2025: $390K published
Quarter from 1 Apr 2025: $350K published
Quarter from 1 Jul 2025: $360K published
Quarter from 1 Oct 2025: $280K published
Quarter from 1 Jan 2026: $350K published
Quarter from 1 Apr 2026: $340K published
Quarter from 1 Jul 2026: $280K published
Quarter from 1 Oct 2026: $300K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $1.7B (30 Sep 2026), 1.2× its normal quarter; higher than 99% of its own history.
  • Insider net buying (open market): Insiders sold a net $34.1M in the last 12 months (the 12 months before: -$13.6M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 41 published in the last 12 months, -35% on the 12 months before.
  • Revenue per quarter: Revenue $1.7B in the latest quarter, +10% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 9 sales, $10.9M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
10 Nov 2026Daniel J. LippisCVP, TAVRSellplanned in advance (10b5-1); after exercising options619$104.25$65KForm 4
9 Nov 2026Bernard J ZovighianCEOSellplanned in advance (10b5-1); after exercising options23,100$103.02$2.4MForm 4
9 Nov 2026Donald E Bobo JrCVP,Strategy/Corp DevelopmentSellplanned in advance (10b5-1); after exercising options48,900$103.05$5.0MForm 4
8 Oct 2026Daniel J. LippisCVP, TAVRSellplanned in advance (10b5-1); after exercising options619$85.65$53KForm 4
11 Sep 2026Daniel J. LippisCVP, TAVRSellplanned in advance (10b5-1); after exercising options619$87.51$54KForm 4
31 Aug 2026Andrew M. DahlSVP, Corporate ControllerSell544$91.06$50KForm 4
28 Aug 2026Annette BrulsCVP, EMEACLASell2,644$89.98$238KForm 4
26 Aug 2026Wayne MarkowitzCVP, JAPACSell1,240$91.47$113KForm 4

1,332 institutions reported shares at the end of Q3 2026, 88% of the shares outstanding; 107 opened a position, 99 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.58.7M10.2%$5.1B-43K-0.1%
Vanguard Capital Management LLC37.7M6.56%$3.3B+102K+0.3%
State Street Corp26.5M4.62%$2.3B+224K+0.9%
Vanguard Portfolio Management LLC26.5M4.61%$2.3B+72K+0.3%
JPMorgan Chase & Co24.5M4.25%$2.2B+1.7M+7.4%
Wellington Management Group LLP16.9M2.94%$1.5B+49K+0.3%
Geode Capital Management, LLC15.6M2.71%$1.3B+169K+1.1%
Ninety One UK Ltd11.9M2.08%$1.0B-394K-3.2%
Bank of New York Mellon Corp11.3M1.96%$973.7M-2.8M-20%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main10.7M1.86%$923.7M-2.3M-18%

Company events

All 26 company events

In 12 months: 3 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
19 Nov 2026Entered Amended and Restated Five Year Credit Agreement with Bank of America, N.A. as Administrative Agent, amending and restating the Jul 15, 2022 credit agreementSame filing: took on new debt8-K
28 Aug 2026Director or officer change8-K
8 May 2026Director or officer changeSame filing: shareholder vote results8-K
4 May 2026Director or officer change8-K
30 Oct 2025Director or officer change8-K
24 Jul 2025Director or officer change8-K
8 May 2025Director or officer changeSame filing: shareholder vote results8-K
10 Jul 2024Director or officer change8-K

362 open postings; careers site tracked since 21 Nov 2026. Most in Sales & business development 9%, Software engineering 9%, Manufacturing & production 7%, Test, quality & reliability 6%.

PostedJobLocation
21 Nov 2026or earlierAnalyst, Data Management, BD Advanced Patient MonitoringDominican Republic-Nave 15-Bachata
21 Nov 2026or earlierAssoc Valve Treatment OperatorSingapore
21 Nov 2026or earlierManager, Professional Education, BD Advanced Patient MonitoringChina-Shanghai
21 Nov 2026or earlierProduct SpecialistChina-Xi'an-Field
21 Nov 2026or earlierKey Account ManagerSales & business developmentChina-Shanghai-Field
21 Nov 2026or earlierSenior Specialist, Sales, BD Advanced Patient MonitoringSales & business developmentChina-Changsha-Field
21 Nov 2026or earlierAssociate Heart Valve SpecialistSingapore
21 Nov 2026or earlierSenior Specialist Sales, BD Advanced Patient MonitoringSales & business developmentChina-Zhengzhou-Field

Reported lobbying spend: $300K in Q3 2026, $280K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
13 Nov 2026NewMarshall & Popp, LLCfor Edwards Lifesciences, LLCIssues related to medical device manufacturing, federal health program reimbursement, trade and tariffs.Health issues, Medicare/Medicaid, Taxation, Budget, TradeFiling
1 May 2026NewAkin Gump Strauss Hauer & Feldfor Edwards Lifesciences LLCTrade policy and tariffs.TradeFiling
15 Jul 2021NewAvenue Solutionsfor Edwards Lifesciences LLCIssues related to the CMS Rule: Medicare Coverage of Innovative TechnologyMedicare/MedicaidFiling
31 Dec 2020EndedOlsson, Frank, Weeda, Terman & Matz, PCfor Edwards LifesciencesCMS reimbursement of medical technologyHealth issues, Medicare/MedicaidFiling
30 Jun 2019EndedCapitol Counsel LLCfor Edwards Lifesciences, LLCIssues pertaining to the National Coverage decision for aortic valvular disease.Medicare/MedicaidFiling
30 Jun 2019EndedAlpine Group Partners, LLC.for Edwards LifesciencesIssues related to medical device tax repeal; Issues related to diagnosis and treatment of structural heart disease; Issues related to coverage of medical devices Breakthrough technology designation associated with medicare reimbursementTaxation, Health issues, Medicare/MedicaidFiling
15 Sep 2018NewBGR Government Affairsfor Edwards Lifesciences LLCProvide analysis and strategic advocacy support services to Edwards Lifesciences public policy priorities, including FDA regulatory and CMS coverage and reimbursement issuesHealth issuesFiling
1 Mar 2018NewCapitol Counsel LLCfor Edwards Lifesciences, LLCIssues pertaining to the National Coverage decision for aortic valvular disease.Medicare/MedicaidFiling

The 5 newest of 348 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Mar 2026confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Edwards Lifesciences (EW): spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year, while it had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year. Two unrelated kinds of activity within 19 days.

  • Financials: Quarterly capital spending jump, became public on 26 Feb 2026
  • Short interest and volume: Short interest spike, became public on 11 Mar 2026
2023-12-31: $88.3M2024-03-31: $65.3M2024-06-30: $85.4M2024-09-30: $51.9M2024-12-31: $49.8M2025-03-31: $56.0M2025-06-30: $49.3M2025-09-30: $57.5M2025-12-31: $97.4M
The quarter ended 31 Dec 2025 against the 8 quarters before it. this quarterearliernormal: $56.8M
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 26 Feb 2026

Edwards Lifesciences spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year.

This period
$97.4M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$56.8M
Typical spread (median absolute deviation)
$7.2M
How far from its usual level
+3.8
Same quarter last year
$49.8M
History used
3,562 days
2023-12-31: $88.3M2024-03-31: $65.3M2024-06-30: $85.4M2024-09-30: $51.9M2024-12-31: $49.8M2025-03-31: $56.0M2025-06-30: $49.3M2025-09-30: $57.5M2025-12-31: $97.4M
the quarter ended 31 Dec 20258 earlier quartersnormal: $56.8M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 11 Mar 2026

Edwards Lifesciences had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year.

This period
12.4M (the 27 Feb 2026 report)
Normal report (median of 24 earlier)
7.9M
Typical spread (median absolute deviation)
675K
How far from its usual level
+4.5
Same report last year
8.5M
History used
2,982 days
2025-02-28: 8.5M2025-03-14: 9.5M2025-03-31: 9.5M2025-04-15: 7.9M2025-04-30: 8.2M2025-05-15: 7.4M2025-05-30: 5.8M2025-06-13: 6.1M2025-06-30: 7.2M2025-07-15: 6.9M2025-07-31: 8.0M2025-08-15: 8.1M2025-08-29: 10.4M2025-09-15: 7.3M2025-09-30: 7.5M2025-10-15: 7.8M2025-10-31: 9.1M2025-11-14: 9.8M2025-11-28: 7.0M2025-12-15: 5.6M2025-12-31: 7.1M2026-01-15: 7.9M2026-01-30: 8.1M2026-02-13: 7.9M2026-02-27: 12.4M
the 27 Feb 2026 report24 earlier reportsnormal: 7.9M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 16 Nov 2026Lobbying record

    EDWARDS LIFESCIENCES, LLC: new lobbying registration (MARSHALL & POPP, LLC) (dated 13 Nov 2026)

  2. 28 Aug 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 28 Aug 2026Filings record

    Director or officer change

  4. 14 Aug 2026Institutional holdings record

    Aristotle Capital Management, LLC opened a $784.0M position (2026Q2 13F)

  5. 30 Jun 2026Lobbying record

    EDWARDS LIFESCIENCES LLC: new lobbying registration (AKIN GUMP STRAUSS HAUER & FELD) (dated 1 May 2026)

  6. 8 May 2026Filings record

    Director or officer change

  7. 4 May 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 4 May 2026Filings record

    Director or officer change

  9. 17 Mar 2026several at once

    spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year, while it had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year. Two unrelated kinds of activity within 19 days.

    See the evidence (2 changes)

    Financials: Quarterly capital spending jump became public on 26 Feb 2026

    Edwards Lifesciences spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year.

    This period
    $97.4M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $56.8M
    Typical spread (median absolute deviation)
    $7.2M
    How far from its usual level
    +3.8
    Same quarter last year
    $49.8M
    History used
    3,562 days
    2023-12-31: $88.3M2024-03-31: $65.3M2024-06-30: $85.4M2024-09-30: $51.9M2024-12-31: $49.8M2025-03-31: $56.0M2025-06-30: $49.3M2025-09-30: $57.5M2025-12-31: $97.4M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $56.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 11 Mar 2026

    Edwards Lifesciences had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year.

    This period
    12.4M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    7.9M
    Typical spread (median absolute deviation)
    675K
    How far from its usual level
    +4.5
    Same report last year
    8.5M
    History used
    2,982 days
    2025-02-28: 8.5M2025-03-14: 9.5M2025-03-31: 9.5M2025-04-15: 7.9M2025-04-30: 8.2M2025-05-15: 7.4M2025-05-30: 5.8M2025-06-13: 6.1M2025-06-30: 7.2M2025-07-15: 6.9M2025-07-31: 8.0M2025-08-15: 8.1M2025-08-29: 10.4M2025-09-15: 7.3M2025-09-30: 7.5M2025-10-15: 7.8M2025-10-31: 9.1M2025-11-14: 9.8M2025-11-28: 7.0M2025-12-15: 5.6M2025-12-31: 7.1M2026-01-15: 7.9M2026-01-30: 8.1M2026-02-13: 7.9M2026-02-27: 12.4M
    the 27 Feb 2026 report24 earlier reportsnormal: 7.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  10. 11 Mar 2026Short interest and volume change

    had 12.4M shares sold short in the 27 Feb 2026 report, 1.5× the same report last year.

    Same report last year: 8.5M; its normal report is 7.9M.

    See the evidence
    This period
    12.4M (the 27 Feb 2026 report)
    Normal report (median of 24 earlier)
    7.9M
    Typical spread (median absolute deviation)
    675K
    How far from its usual level
    +4.5
    Same report last year
    8.5M
    History used
    2,982 days
    2025-02-28: 8.5M2025-03-14: 9.5M2025-03-31: 9.5M2025-04-15: 7.9M2025-04-30: 8.2M2025-05-15: 7.4M2025-05-30: 5.8M2025-06-13: 6.1M2025-06-30: 7.2M2025-07-15: 6.9M2025-07-31: 8.0M2025-08-15: 8.1M2025-08-29: 10.4M2025-09-15: 7.3M2025-09-30: 7.5M2025-10-15: 7.8M2025-10-31: 9.1M2025-11-14: 9.8M2025-11-28: 7.0M2025-12-15: 5.6M2025-12-31: 7.1M2026-01-15: 7.9M2026-01-30: 8.1M2026-02-13: 7.9M2026-02-27: 12.4M
    the 27 Feb 2026 report24 earlier reportsnormal: 7.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  11. 26 Feb 2026Financials change

    spent $97.4M on capital projects in the quarter ended 31 Dec 2025, 2.0× the same quarter last year.

    Same quarter last year: $49.8M; its normal quarter is $56.8M.

    See the evidence
    This period
    $97.4M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $56.8M
    Typical spread (median absolute deviation)
    $7.2M
    How far from its usual level
    +3.8
    Same quarter last year
    $49.8M
    History used
    3,562 days
    2023-12-31: $88.3M2024-03-31: $65.3M2024-06-30: $85.4M2024-09-30: $51.9M2024-12-31: $49.8M2025-03-31: $56.0M2025-06-30: $49.3M2025-09-30: $57.5M2025-12-31: $97.4M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $56.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  12. 30 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 30 Oct 2025Filings record

    Director or officer change

  14. 24 Jul 2025Filings record

    Director or officer change

  15. 8 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 8 May 2025Filings record

    Director or officer change

  17. 24 Jan 2025Institutional holdings record

    JENNISON ASSOCIATES LLC opened a $556.0M position (2024Q4 13F)

  18. 10 Jul 2024Filings record

    Director or officer change

  19. 17 Jun 2024Filings record

    Director or officer change

  20. 15 May 2024Institutional holdings record

    Point72 Asset Management, L.P. opened a $284.0M position (2024Q1 13F)

  21. 14 May 2024Institutional holdings record

    Winslow Capital Management, LLC opened a $483.0M position (2024Q1 13F)

  22. 8 May 2024Insiders record

    Zovighian Bernard J (CEO) bought 580 shares of EW ($49,751) (dated 7 May 2024)

  23. 26 Mar 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 26 Mar 2024Filings record

    Director or officer change

  25. 15 May 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 15 May 2023Filings record

    Director or officer change

  27. 25 Mar 2023Short interest and volume change

    had 16.9M shares sold short in the 15 Mar 2023 report, 3.8× the same report last year.

    Same report last year: 4.5M; its normal report is 6.6M.

    See the evidence
    This period
    16.9M (the 15 Mar 2023 report)
    Normal report (median of 24 earlier)
    6.6M
    Typical spread (median absolute deviation)
    1.7M
    How far from its usual level
    +4.2
    Same report last year
    4.5M
    History used
    1,902 days
    2022-03-15: 4.5M2022-03-31: 4.5M2022-04-14: 5.7M2022-04-29: 4.9M2022-05-13: 5.1M2022-05-31: 6.6M2022-06-15: 5.9M2022-06-30: 6.2M2022-07-15: 6.7M2022-07-29: 5.5M2022-08-15: 5.0M2022-08-31: 3.7M2022-09-15: 6.5M2022-09-30: 7.6M2022-10-14: 7.4M2022-10-31: 8.1M2022-11-15: 10.6M2022-11-30: 11.0M2022-12-15: 14.0M2022-12-30: 15.3M2023-01-13: 13.9M2023-01-31: 13.7M2023-02-15: 12.0M2023-02-28: 12.8M2023-03-15: 16.9M
    the 15 Mar 2023 report24 earlier reportsnormal: 6.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 10 Feb 2023Short interest and volume change

    had 13.7M shares sold short in the 31 Jan 2023 report, 2.4× the same report last year.

    Same report last year: 5.8M; its normal report is 6.3M.

    See the evidence
    This period
    13.7M (the 31 Jan 2023 report)
    Normal report (median of 24 earlier)
    6.3M
    Typical spread (median absolute deviation)
    1.2M
    How far from its usual level
    +4.1
    Same report last year
    5.8M
    History used
    1,859 days
    2022-01-31: 5.8M2022-02-15: 6.3M2022-02-28: 5.6M2022-03-15: 4.5M2022-03-31: 4.5M2022-04-14: 5.7M2022-04-29: 4.9M2022-05-13: 5.1M2022-05-31: 6.6M2022-06-15: 5.9M2022-06-30: 6.2M2022-07-15: 6.7M2022-07-29: 5.5M2022-08-15: 5.0M2022-08-31: 3.7M2022-09-15: 6.5M2022-09-30: 7.6M2022-10-14: 7.4M2022-10-31: 8.1M2022-11-15: 10.6M2022-11-30: 11.0M2022-12-15: 14.0M2022-12-30: 15.3M2023-01-13: 13.9M2023-01-31: 13.7M
    the 31 Jan 2023 report24 earlier reportsnormal: 6.3M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 26 Jan 2023Short interest and volume change

    had 13.9M shares sold short in the 13 Jan 2023 report, 2.6× the same report last year.

    Same report last year: 5.4M; its normal report is 6.0M.

    See the evidence
    This period
    13.9M (the 13 Jan 2023 report)
    Normal report (median of 24 earlier)
    6.0M
    Typical spread (median absolute deviation)
    948K
    How far from its usual level
    +5.6
    Same report last year
    5.4M
    History used
    1,841 days
    2022-01-14: 5.4M2022-01-31: 5.8M2022-02-15: 6.3M2022-02-28: 5.6M2022-03-15: 4.5M2022-03-31: 4.5M2022-04-14: 5.7M2022-04-29: 4.9M2022-05-13: 5.1M2022-05-31: 6.6M2022-06-15: 5.9M2022-06-30: 6.2M2022-07-15: 6.7M2022-07-29: 5.5M2022-08-15: 5.0M2022-08-31: 3.7M2022-09-15: 6.5M2022-09-30: 7.6M2022-10-14: 7.4M2022-10-31: 8.1M2022-11-15: 10.6M2022-11-30: 11.0M2022-12-15: 14.0M2022-12-30: 15.3M2023-01-13: 13.9M
    the 13 Jan 2023 report24 earlier reportsnormal: 6.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 12 Jan 2023Short interest and volume change

    had 15.3M shares sold short in the 30 Dec 2022 report, 2.8× the same report last year.

    Same report last year: 5.5M; its normal report is 5.8M.

    See the evidence
    This period
    15.3M (the 30 Dec 2022 report)
    Normal report (median of 24 earlier)
    5.8M
    Typical spread (median absolute deviation)
    758K
    How far from its usual level
    +8.5
    Same report last year
    5.5M
    History used
    1,827 days
    2021-12-15: 5.5M2022-01-14: 5.4M2022-01-31: 5.8M2022-02-15: 6.3M2022-02-28: 5.6M2022-03-15: 4.5M2022-03-31: 4.5M2022-04-14: 5.7M2022-04-29: 4.9M2022-05-13: 5.1M2022-05-31: 6.6M2022-06-15: 5.9M2022-06-30: 6.2M2022-07-15: 6.7M2022-07-29: 5.5M2022-08-15: 5.0M2022-08-31: 3.7M2022-09-15: 6.5M2022-09-30: 7.6M2022-10-14: 7.4M2022-10-31: 8.1M2022-11-15: 10.6M2022-11-30: 11.0M2022-12-15: 14.0M2022-12-30: 15.3M
    the 30 Dec 2022 report24 earlier reportsnormal: 5.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 28 Dec 2022Short interest and volume change

    had 14.0M shares sold short in the 15 Dec 2022 report, 2.5× the same report last year.

    Same report last year: 5.5M; its normal report is 5.8M.

    See the evidence
    This period
    14.0M (the 15 Dec 2022 report)
    Normal report (median of 24 earlier)
    5.8M
    Typical spread (median absolute deviation)
    751K
    How far from its usual level
    +7.4
    Same report last year
    5.5M
    History used
    1,812 days
    2021-11-30: 5.7M2021-12-15: 5.5M2022-01-14: 5.4M2022-01-31: 5.8M2022-02-15: 6.3M2022-02-28: 5.6M2022-03-15: 4.5M2022-03-31: 4.5M2022-04-14: 5.7M2022-04-29: 4.9M2022-05-13: 5.1M2022-05-31: 6.6M2022-06-15: 5.9M2022-06-30: 6.2M2022-07-15: 6.7M2022-07-29: 5.5M2022-08-15: 5.0M2022-08-31: 3.7M2022-09-15: 6.5M2022-09-30: 7.6M2022-10-14: 7.4M2022-10-31: 8.1M2022-11-15: 10.6M2022-11-30: 11.0M2022-12-15: 14.0M
    the 15 Dec 2022 report24 earlier reportsnormal: 5.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 10 Dec 2022Short interest and volume change

    had 11.0M shares sold short in the 30 Nov 2022 report, 1.9× the same report last year.

    Same report last year: 5.7M; its normal report is 5.7M.

    See the evidence
    This period
    11.0M (the 30 Nov 2022 report)
    Normal report (median of 24 earlier)
    5.7M
    Typical spread (median absolute deviation)
    643K
    How far from its usual level
    +5.5
    Same report last year
    5.7M
    History used
    1,797 days
    2021-11-15: 5.5M2021-11-30: 5.7M2021-12-15: 5.5M2022-01-14: 5.4M2022-01-31: 5.8M2022-02-15: 6.3M2022-02-28: 5.6M2022-03-15: 4.5M2022-03-31: 4.5M2022-04-14: 5.7M2022-04-29: 4.9M2022-05-13: 5.1M2022-05-31: 6.6M2022-06-15: 5.9M2022-06-30: 6.2M2022-07-15: 6.7M2022-07-29: 5.5M2022-08-15: 5.0M2022-08-31: 3.7M2022-09-15: 6.5M2022-09-30: 7.6M2022-10-14: 7.4M2022-10-31: 8.1M2022-11-15: 10.6M2022-11-30: 11.0M
    the 30 Nov 2022 report24 earlier reportsnormal: 5.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 8 Dec 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  34. 8 Dec 2022Filings record

    Director or officer change

  35. 26 Nov 2022Short interest and volume change

    had 10.6M shares sold short in the 15 Nov 2022 report, 1.9× the same report last year.

    Same report last year: 5.5M; its normal report is 5.7M.

    See the evidence
    This period
    10.6M (the 15 Nov 2022 report)
    Normal report (median of 24 earlier)
    5.7M
    Typical spread (median absolute deviation)
    643K
    How far from its usual level
    +5.1
    Same report last year
    5.5M
    History used
    1,782 days
    2021-10-29: 6.9M2021-11-15: 5.5M2021-11-30: 5.7M2021-12-15: 5.5M2022-01-14: 5.4M2022-01-31: 5.8M2022-02-15: 6.3M2022-02-28: 5.6M2022-03-15: 4.5M2022-03-31: 4.5M2022-04-14: 5.7M2022-04-29: 4.9M2022-05-13: 5.1M2022-05-31: 6.6M2022-06-15: 5.9M2022-06-30: 6.2M2022-07-15: 6.7M2022-07-29: 5.5M2022-08-15: 5.0M2022-08-31: 3.7M2022-09-15: 6.5M2022-09-30: 7.6M2022-10-14: 7.4M2022-10-31: 8.1M2022-11-15: 10.6M
    the 15 Nov 2022 report24 earlier reportsnormal: 5.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 21 Jul 2022Filings record

    A major agreement ended

  37. 25 Nov 2021Insiders record

    VALERIANI NICHOLAS J (director) bought 1,500 shares of EW ($168,345) (dated 24 Nov 2021)

  38. 16 Jul 2021Lobbying record

    EDWARDS LIFESCIENCES LLC: new lobbying registration (AVENUE SOLUTIONS) (dated 15 Jul 2021)

  39. 5 May 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  40. 5 May 2021Filings record

    Director or officer change

Showing the newest 40 of 86 entries; narrow the window or the kind of data to see older ones.

Not listed: 724 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001099800
Ticker
EW
Domain
edwards.com
Employer name
Edwards Lifesciences Export Puerto Rico Corporation, EDWARDS LIFESCIENCES LLC, Edwards Lifesciences Technology Sarl (3 unverified)
Fein
66-0588804, 98-0506096 (2 unverified)
Hq location
CA|IRVINE|92614 (1 unverified)
Lobbying client
edwards lifesciences
Name
CVG CONTROLLED INC, Edwards Lifesciences Corp, Edwards Lifesciences Holding, Inc, Edwards Lifesciences (Japan) LLC and 3 more
Uei
ER1MCQ4E1677, MR4FCKSNGRC1
Wikidata
Q16966841
Wikipedia
Edwards Lifesciences
  • DOL H-1B labor condition applications and PERM certifications1053 data points1 Oct 2019 to 28 Sep 2026
  • Federal lobbying disclosures (LDA)19 records, 246 data points15 Jul 2004 to 13 Nov 2026
  • SEC Form 13F institutional holdings7 records, 481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)126 records2 Feb 2016 to 19 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1230 data points31 Dec 2007 to 31 Oct 2026
  • SEC Form 4 insider transactions626 records, 1968 data points7 Jan 2016 to 10 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards13614 data points1 Oct 2007 to 20 Nov 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026